ESMO 2026 | How are ADCs & CDK inhibitors reshaping metastatic breast cancer treatment?

There’s many in the different group for… for metastatic breast cancer. I’m involved in a lot of study in metastatic breast cancer because we should have more improvement. In triple negative breast cancer, of course, we have the data about ADC. And how it translates with improved PFS on overall survival with that TDXD. And moreover, we also have the activity in brain mets. Brain mets are very frequent in triple negative brain cancer. As in HER2-POSITIVE metastatic breast cancer. Up to 50 % of the patients. So these are good, new. I would say we have other treatment options. New ADC from China. They are, I think, we see very interesting results. But we have to, perhaps we need more follow-up. About the duration of therapy and treatment administered after progression. So this will be important. And for ER-POSITIVE disease, of course, we have post-CDK4-6 inhibitor. First line we have abemaciclib, a new CDK, very specific of CDK4, and in combination with fulvestrant. It was superior to the control arm fulvestrant monotherapy or eczemesta neverolimus. So this is very important. Because as we are moving CDK for 6 inhibitor in the adjuvant setting. We need more drug ACTIVE in the metastatic setting. And of course we have the update of Nathalie. 6 years. We have this improvement in survival. So even if it was not, I would say, hierarchical. But it’s important. And then I would that was the main to me. Just many other things. Because we have. A date of former clinical trial. Presented at San Antonio and ASCO. It adds something. But the main new treatment was abemaciclib. And the brain meds. This morning was a very good session about brain mets.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.